October 3, 2022 05:34 AM EDTUpdated 07:29 AM

#AAO22: On the heels of PhIII launch, Aura details second administration route of its ocular oncology drug

Kyle LaHucik

Senior Reporter

CHICAGO — Ahead of its fourth quarter pivotal trial launch, Aura Biosciences detailed some interim data from its ongoing Phase II trial of an eye …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#AAO22: On the heels of PhIII launch, Aura details second administration route of its ocular oncology drug

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

#AAO22: On the heels of PhI­II launch, Au­ra de­tails sec­ond ad­min­is­tra­tion route of its oc­u­lar on­col­o­gy drug

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

#AAO22: On the heels of PhIII launch, Aura details second administration route of its ocular oncology drug

CagriSema’s weight loss data disappointed. What does Novo do next?

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify